Astellas Pharma ADR (OP:ALPMY)

14.67 -0.10 (-0.69%)

Streaming Delayed Price Updated: 3:26 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma ADR

< Previous 1 2 3 Next >

Why Shares of Annexon Are Plummeting Thursday ↗

May 25, 2023

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

Via The Motley Fool

Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories ↗

May 15, 2023

Bloomberg

Via Benzinga

Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback ↗

May 15, 2023

The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes

Via Benzinga

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗

May 01, 2023

These three biotech stocks were on the volatile side today.

Via The Motley Fool

Astellas' Menopause Drug Under FDA Review ↗

August 18, 2022

Via Benzinga

Sutro Biopharma Stock Surges On Cancer Treatment Pact ↗

June 28, 2022

Via Benzinga

Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold ↗

June 27, 2022

Via Benzinga

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial ↗

March 15, 2022

Via Benzinga

Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% ↗

May 01, 2023

Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced

Via Benzinga

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma ↗

May 01, 2023

The company is working on a treatment for the eye disease known as geographic atrophy.

Via Investor's Business Daily

First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗

May 01, 2023

Benzinga

Via Benzinga

Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move ↗

May 01, 2023

Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts.

Via Benzinga

Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' ↗

May 01, 2023

Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of

Via Benzinga

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗

April 04, 2023

Via Benzinga

Japanese Government Urges China To Release Astellas Pharma's Employee ↗

March 27, 2023

The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was...

Via Benzinga

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug ↗

March 17, 2023

Via Benzinga

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation ↗

March 13, 2023

Via Benzinga

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover ↗

February 27, 2023

The potential deal follows rumors last year that Merck could buy Seagen.

Via Investor's Business Daily

Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them ↗

February 13, 2023

Super Bowl LVII aired Sunday Feb. 12, 2023 and featured dozens of commercials advertising products and showcasing new movies and television shows. The commercials also featured many celebrity cameos...

Via Benzinga

Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts ↗

January 31, 2023

Via Benzinga

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

What Is Going on With Taysha Gene (TSHA) Stock Today? ↗

October 25, 2022

Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases.

Via InvestorPlace

Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs ↗

October 25, 2022

Via Benzinga

Seagen Shares Jump On Positive Data From Urothelial Cancer Trial ↗

July 26, 2022

Via Benzinga

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies ↗

May 09, 2022

Via Benzinga

Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer ↗

April 13, 2022

The

Via Benzinga

Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing ↗

March 07, 2022

Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor...

Via Benzinga

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients ↗

February 15, 2022

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.